SCHEMBL614573

SCHEMBL614573

CS(=O)(=O)OCc1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
PARP10 Q53GL7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP1A2 P05177 1/20 0.44
TSHR P16473 1/20 0.44
SYK P43405 2/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
AURKB Q96GD4 1/20 0.42
INCENP Q9NQS7 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31539875 1.00 LMNA (0.50) LMNATDP1ALDH1A1SMN1; SMN2KDM4E
Carbamic Acid SCHEMBL7600209 0.91 PARP10 (0.51) LMNATDP1ALDH1A1SMN1; SMN2NPC1
SCHEMBL2082694 0.82 KDM4E (0.49) LMNATDP1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL1044520 0.82 LMNA (0.55) LMNATDP1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL11106613 0.81 SMN1; SMN2 (0.46) LMNATDP1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL27163416 0.81 CYP1A2 (0.42) LMNATDP1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL4515694 0.79 KMT2A (0.53) LMNATDP1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL25321212 0.79 KCNH2 (0.44) LMNATDP1ALDH1A1KDM4ECYP1A2
SCHEMBL27163467 0.78 CYP1A2 (0.40) LMNATDP1SMN1; SMN2KDM4EL3MBTL1
SCHEMBL11530185 0.77 LMNA (0.44) LMNATDP1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1073428-B1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARMA CO LTD (KR) 2004-10-27 EP claimed
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
CN-106687458-B Substituted oxopyridine derivatives 拜耳制药股份公司 2020-10-27 CN disclosed
EP-3197872-B1 (2H)-2-OXOPYRIDINES AS FAKTOR XIA-INHIBITORS FOR TREATING THROMBOTIC DISEASES Bayer Pharma AG (DE) 2019-01-30 EP disclosed
US-10167280-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-01-01 US disclosed
US-10071995-B2 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-09-11 US disclosed
EP-3197889-B1 SUBSTITUTED OXOPYRIDINE DERIVATIVES Bayer Pharma AG (DE) 2018-08-01 EP disclosed
US-20180127401-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-10 US disclosed
US-20060287341-A1 Triazolopyrimidine cannabinoid receptor 1 antagonists BRISTOL-MYERS SQUIBB COMPANY 2006-12-21 US disclosed
EP-1683787-A1 METHOD FOR PRODUCING BACTERICIDAL PYRIDINE COMPOUND AND BACTERICIDAL PYRIDINE COMPOUND Tama Kagaku Kogyo Co., Ltd. (JP) 2006-07-26 EP disclosed
WO-2005044267-A1 ALKYNES II ASTRAZENECA AB (SE) 2005-05-19 WO disclosed
EP-1073428-B1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARMA CO LTD (KR) 2004-10-27 EP disclosed
EP-1073428-A1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES Choongwae Pharma Co., Ltd. (KR) 2001-02-07 EP disclosed
WO-1999055318-A1 DIHYDROXYPHENYL DERIVATIVES FOR HEPATOPROTECTION AND TREATMENT OF LIVER DISEASES CHOONGWAE PHARM. CO., LTD. (KR) 1999-11-04 WO disclosed
US-5506227-A USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS MERCK FROSST CANADA, INC. (CA) 1996-04-09 US disclosed
EP-0639181-A1 PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS MERCK FROSST CANADA INC. (CA) 1995-02-22 EP disclosed
WO-1993021158-A1 PYRIDINE-SUBSTITUTED BENZYL ALCOHOLS AS LEUKOTRIENE ANTAGONISTS MERCK FROSST CANADA INC. (CA) 1993-10-28 WO disclosed
US-4171325-A Chemical process SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287341-A1 Triazolopyrimidine cannabinoid receptor 1 antagonists CNR1, CNR2, GPR68 LMNA 4614/4885TDP1 988/4885ALDH1A1 1549/4885
US-10167280-B2 Substituted oxopyridine derivatives OGFOD1, PNPO, VASP LMNA 2253/4885TDP1 266/4885ALDH1A1 1944/4885
US-20180127401-A1 SUBSTITUTED OXOPYRIDINE DERIVATIVES OGFOD1, PNPO, VASP LMNA 2253/4885TDP1 266/4885ALDH1A1 1944/4885
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 LMNA 3817/4885TDP1 3576/4885ALDH1A1 1658/4885
US-10071995-B2 Substituted oxopyridine derivatives OGFOD1, PNPO, VASP LMNA 2253/4885TDP1 266/4885ALDH1A1 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.